For the quarter ending 2025-09-30, TCRX made $2,511K in revenue. -$35,710K in net income. Net profit margin of -1422.14%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Collaboration and license revenue | 2,511 | 3,076 | 2,171 | 1,049 |
| Research and development | 31,689 | 32,634 | 29,788 | 26,262 |
| General and administrative | 7,874 | 9,095 | 8,633 | 7,409 |
| Total operating expenses | 39,563 | 41,729 | 38,421 | 33,671 |
| Loss from operations | -37,052 | -38,653 | -36,250 | -32,622 |
| Interest and other income, net | 2,041 | 2,390 | 2,802 | 3,693 |
| Interest expense | 699 | 689 | 679 | 958 |
| Total other income | 1,342 | 1,701 | 2,123 | 2,735 |
| Net loss | -35,710 | -36,952 | -34,127 | -29,887 |
| Net loss per share, basic | -0.28 | -0.28 | -0.26 | -0.25 |
| Net loss per share, diluted | -0.28 | -0.28 | -0.26 | -0.25 |
| Weighted-average common shares outstanding, basic | 129,835,938 | 129,730,451 | 129,678,572 | 118,700,362 |
| Weighted-average common shares outstanding, diluted | 129,835,938 | 129,730,451 | 129,678,572 | 118,700,362 |
TScan Therapeutics, Inc. (TCRX)
TScan Therapeutics, Inc. (TCRX)